BMS-345541 Hydrochloride: Selective IKK Inhibitor for NF-κB Pathway Studies

Executive Summary: BMS-345541 hydrochloride is a potent and selective inhibitor of IκB kinase isoforms IKK-1 and IKK-2, with IC₅₀ values of 4 μM and 0.3 μM, respectively (APExBIO product sheet). It acts by binding an allosteric site, thereby blocking NF-κB-dependent transcription of key pro-inflammatory cytokines, including TNFα and IL-1β (Zhao et al., 2025). BMS-345541 demonstrates high selectivity, showing no inhibition of unrelated kinases, and is water-soluble at ≥60 mg/mL. The compound induces apoptosis and G2/M arrest in T-ALL cell models, suggesting utility in overcoming chemoresistance (internal benchmark). Stable storage is achieved at -20°C, and in vivo studies confirm 100% oral bioavailability and potent TNFα inhibition. These properties position BMS-345541 hydrochloride as a critical tool for NF-κB, inflammation, and cancer research.

Biological Rationale

The NF-κB pathway orchestrates immune responses, inflammation, cell survival, and proliferation. Dysregulation of this pathway is implicated in chronic inflammatory diseases, autoimmune conditions, and cancers, notably T-cell acute lymphoblastic leukemia (T-ALL) (Zhao et al., 2025). IκB kinase (IKK) complex activation is a rate-limiting step for NF-κB nuclear translocation and subsequent transcription of pro-inflammatory cytokines such as TNFα, IL-1β, IL-6, and IL-8. Selective inhibition of IKK, as achieved with BMS-345541 hydrochloride, allows for precise modulation of this pathway, offering a tractable approach to dissect inflammation and oncogenic processes at the molecular level. Research-grade inhibitors like BMS-345541 are thus foundational for mechanistic and translational studies in both basic and applied biosciences (see further mechanistic context).

Mechanism of Action of BMS-345541 hydrochloride

BMS-345541 hydrochloride is a small-molecule inhibitor that targets the IKK complex by binding to an allosteric site distinct from the ATP-binding pocket. The compound exhibits IC₅₀ values of 0.3 μM for IKK-2 and 4 μM for IKK-1, demonstrating a strong preference for IKK-2. The inhibitor does not affect other serine/threonine or tyrosine kinases at experimental concentrations (≤10 μM) (APExBIO). This specificity ensures blockade of the stimulus-induced phosphorylation of IκB, thereby preventing NF-κB activation and nuclear translocation. As a result, downstream transcription of pro-inflammatory cytokines is suppressed, documented both in vitro and in vivo (Zhao et al., 2025). In T-ALL cell lines, this mechanism induces apoptosis and G2/M phase cell cycle arrest, an effect not observed in non-NF-κB-dependent cells (expanded translational insights).

Evidence & Benchmarks

• BMS-345541 hydrochloride inhibits IKK-2 with an IC₅₀ of 0.3 μM and IKK-1 with an IC₅₀ of 4 μM under cell-free kinase assay conditions (APExBIO, product page).
• In cell-based assays, BMS-345541 blocks stimulus-driven phosphorylation of IκBα, thereby inhibiting nuclear NF-κB translocation (Zhao et al., 2025).
• The compound does not inhibit other kinases such as MAPK or JNK, confirming selectivity at concentrations up to 10 μM (see comparative analysis).
• In T-ALL cell models, BMS-345541 induces significant apoptosis and G2/M arrest at 1–10 μM, measured by flow cytometry and caspase activation assays (internal use-case).
• Oral administration in rodent models yields 100% bioavailability and effective TNFα inhibition, as quantified by ELISA in serum samples (Zhao et al., 2025).

Applications, Limits & Misconceptions

BMS-345541 hydrochloride is widely used for:

• Dissecting the IKK/NF-κB signaling axis in inflammation research (mechanistic review).
• Evaluating chemoresistance and apoptosis induction in T-ALL and other NF-κB-dependent cancers.
• Preclinical modeling of pro-inflammatory cytokine inhibition in animal models.
• Screening for anti-inflammatory or anti-angiogenic interventions, as in airway stent development (Zhao et al., 2025).

However, certain boundaries and misconceptions persist:

Common Pitfalls or Misconceptions

• BMS-345541 hydrochloride does not inhibit unrelated kinases (e.g., PI3K, MAPK, JNK) at ≤10 μM; off-target effects are minimal only within validated concentrations.
• It is not a pan-NF-κB inhibitor; efficacy is strictly IKK complex-dependent and does not block non-canonical NF-κB activation routes.
• Compound solubility is high in water (≥60 mg/mL) but poor in ethanol and DMSO; inappropriate solvents reduce assay reproducibility.
• Long-term storage of prepared solutions at >-20°C leads to degradation; use fresh solutions for optimal performance.
• In vivo efficacy is model-specific and may not translate across species or tissue types without direct validation.

Workflow Integration & Parameters

For effective use, BMS-345541 hydrochloride (SKU A3248 from APExBIO) should be dissolved in sterile water at concentrations up to 60 mg/mL. For cell-based assays, typical working concentrations range from 0.1–10 μM, with exposure durations from 1–48 hours depending on experimental endpoint. For in vivo studies, oral gavage or intraperitoneal injection is standard, with dosing regimens determined by model and target cytokine kinetics. Stock solutions remain stable at -20°C for several months; avoid repeated freeze–thaw cycles (product reference). For troubleshooting and advanced workflows, see this practical scenario guide, which addresses common laboratory pitfalls and extends the mechanistic details discussed here.

Researchers seeking to design translational assays or verify pathway specificity can consult this mechanistic article, which lays out advanced design strategies beyond basic inhibition studies.

Conclusion & Outlook

BMS-345541 hydrochloride is a precise, research-grade IKK inhibitor with high selectivity for the IKK/NF-κB axis. Its defined activity profile, robust water solubility, and reproducibility make it a mainstay in inflammation, apoptosis, and cancer biology research. As new translational models emerge, particularly in anti-inflammatory stent technology and T-ALL chemoresistance, BMS-345541 hydrochloride will remain a reference compound for dissecting NF-κB-driven pathologies (Zhao et al., 2025). For validated supply and technical support, consult APExBIO, the originating provider of the A3248 kit.